Significance Statement {#s5}
======================

Patients with major depressive disorder are likely to experience problems with functioning in multiple environments: at work or school, in their social life and leisure activities, and in their family and home responsibilities. In particular, patients who do not fully respond to antidepressant treatment may suffer a prolonged loss of functioning. The present article describes the effects of brexpiprazole on functioning, based on pooled data for over 2000 patients from 6 randomized, controlled trials. Among patients with inadequate response to antidepressant treatment, brexpiprazole was shown to improve functioning over 6 weeks compared with placebo. Specifically, benefits were observed for brexpiprazole over placebo in the domains of social and family life.

Introduction {#s6}
============

Major depressive disorder (MDD) is associated with impairments across multiple domains of patient functioning, including work and school (affecting work performance and earnings, for example), social life and leisure activities, and family and home responsibilities ([@CIT0012], [@CIT0011]; [@CIT0010]). In clinical practice, improvement of functioning may lag behind improvement of mood, largely due to unresolved, functionally impairing symptoms such as fatigue, sleep/wake disturbance, and cognitive dysfunction ([@CIT0020]).

Many patients with MDD fail to respond to antidepressant treatment (ADT) ([@CIT0019]). Patients with inadequate response to ADT may experience a prolonged loss of functioning and quality of life ([@CIT0015]). One treatment option for such patients is the use of an adjunctive antipsychotic added to the existing ADT. A meta-analysis of 14 randomized, placebo-controlled studies showed that adjunctive atypical antipsychotics are efficacious for reducing depressive symptoms in MDD ([@CIT0024]). However, the use of adjunctive atypical antipsychotics is associated with tolerability concerns, and little or no benefits have been observed on functioning or quality-of-life outcomes ([@CIT0024]).

Brexpiprazole is a serotonin--dopamine activity modulator that acts as a partial agonist at serotonin 5-HT~1A~ and dopamine D~2~ receptors and as an antagonist at serotonin 5-HT~2A~ and noradrenaline α~1B~/α~2C~ receptors, all with subnanomolar potency ([@CIT0013]). The efficacy and safety of brexpiprazole as adjunct to ADT over 6 weeks have been demonstrated in 4 phase 3 studies (Pyxis, Polaris, Sirius, and Delphinus) ([@CIT0026], [@CIT0027]; [@CIT0005], [@CIT0006]) in which brexpiprazole improved depressive symptoms vs placebo. The present article is a pooled analysis of data from the 4 short-term phase 3 studies, together with 2 short-term phase 2 studies (Studies 211 and 222; [@CIT0025], [@CIT0028]), with the aim of determining the effect of adjunctive brexpiprazole on functioning in patients with inadequate response to ADTs.

Methods {#s7}
=======

This pooled analysis included 6 short-term, randomized, placebo-controlled studies of adjunctive brexpiprazole in patients with MDD and inadequate response to ADTs. Details of the included studies are given in [Table 1](#T1){ref-type="table"}. For a full description of the study designs and selection criteria, please refer to the primary publications ([@CIT0025], [@CIT0026], [@CIT0027], [@CIT0028]; [@CIT0005], [@CIT0006]).

###### 

Brexpiprazole Short-Term Clinical Study Designs for the Adjunctive Treatment of MDD

  Study name (ClinicalTrials.gov identifier)         Design                                                                                                                  Main inclusion criteria for prospective phase                                                                                                                                                                                         Criteria for consistent inadequate response throughout the prospective treatment phase^*a*^                                                                                                                                                                                                            Dosing     Treatment groups (efficacy population^*b*^)
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- --------------------------------------------------------------------------------------------------------------------------------------------------
  **Phase 3**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Pyxis (NCT01360645) ([@CIT0026])                   8-week, single-blind, prospective phase followed by 6-week, randomized, double-blind, placebo-controlled phase          DSM-IV-TR diagnosis of single or recurrent nonpsychotic MDD, current episode ≥8 weeks in duration, history of inadequate response to ADT,^*c*^ and HAM-D~17~ total score ≥18 at screening and at the start of prospective treatment   HAM-D~17~ total score: \<50% reduction from the start to the end of prospective treatment; ≥14 at the end of prospective treatmentCGI-I score: ≥3 at weeks 2, 4, 6, and 8 of prospective treatmentMADRS total score: \<50% reduction from the start to weeks 2, 4, 6, and 8 of prospective treatment   Fixed      **ADT +** brexpiprazole 2 mg/d (n = 175) placebo (n = 178)
  Polaris (NCT01360632) ([@CIT0027])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Fixed      **ADT +** brexpiprazole 1 mg/d (n = 211)brexpiprazole 3 mg/d (n = 213) placebo (n = 203)
  Sirius (NCT02196506) ([@CIT0005])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Fixed      **ADT +** brexpiprazole 2 mg/d (n = 191) placebo (n = 202)
  Delphinus (NCT01727726) ([@CIT0006])               8- or 10-week, double-blind, prospective phase followed by 6-week, randomized, double-blind, placebo-controlled phase   DSM-IV-TR diagnosis of single or recurrent nonpsychotic MDD, current episode ≥8 weeks in duration, history of inadequate response to ADT,^*c*^ and MADRS total score ≥26 at screening and at the start of prospective treatment       CGI-I score: ≥3 at weeks 2, 4, 6, and 8^*d*^ of prospective treatmentMADRS total score: \<50% reduction from the start to weeks 2, 4, 6, and 8^*d*^ of prospective treatment; ≥18 at the end of prospective treatment                                                                                  Flexible   **ADT +** brexpiprazole 2--3 mg/d (n = 191) quetiapine XR 150--300 mg/d (n = 99) placebo (n = 205)
  **Phase 2**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Study 211 (NCT00797966) ([@CIT0025], [@CIT0028])   As for Pyxis, Polaris, and Sirius                                                                                       As for Pyxis, Polaris, and Sirius, except HAM-D~17~ total score ≥18 at the start of prospective treatment only (not at screening)                                                                                                     As for Pyxis, Polaris, and Sirius (retrospectively applied for the pooled analysis)                                                                                                                                                                                                                    Flexible   **ADT +** brexpiprazole 0.15 mg/d (fixed) (n = 45) brexpiprazole 0.5 ± 0.25 mg/d (n = 94) brexpiprazole 1.5 ± 0.5 mg/d (n = 90) placebo (n = 89)
  Study 222 (NCT01052077) ([@CIT0028])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Flexible   **ADT +** brexpiprazole 1--3 mg/d (n = 158)placebo (n = 147)

Abbreviations: ADT, antidepressant treatment; CGI-I, Clinical Global Impressions -- Improvement; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; HAM-D~17~, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery--Åsberg Depression Rating Scale; MDD, major depressive disorder; XR, extended-release.

^*a*^Following an amendment to Pyxis and Polaris.

^*b*^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.

^*c*^An inadequate response to 1 to 3 prior ADTs during the current episode (including any ADT being taken at screening), defined as \<50% improved on a therapeutic dose for an adequate duration (≥6 weeks) according to the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire.

^*d*^And Week 10, if applicable (in this study, to blind the timing of randomization, patients were randomly assigned to an 8- or 10-week prospective treatment phase).

All studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice Guideline and local regulatory requirements. The study protocols were approved by relevant institutional review boards and independent ethics committees. All patients provided written informed consent prior to the start of the studies.

Study Design and Patients {#s8}
-------------------------

Each of the 6 studies had a similar design, comprising an 8- or 10-week prospective treatment phase followed by a 6-week, randomized, double-blind treatment phase for patients who did not adequately respond to prospective treatment ([Table 1](#T1){ref-type="table"}). In the prospective treatment phase, eligible adult outpatients (see [Table 1](#T1){ref-type="table"} for main inclusion criteria) received an investigator-determined, open-label ADT, together with single-blind placebo (in Pyxis, Polaris, Sirius, Study 211, and Study 222) or double-blind placebo (in Delphinus). During this phase, patients were assessed for inadequate response to prospective ADT (see [Table 1](#T1){ref-type="table"} for definitions). Patients who did not meet the criteria for inadequate response (i.e., responders to prospective ADT) continued to receive the same open-label ADT and single- or double-blind placebo until the end of the study; these patients were not randomized or included in the analyses. Patients who did meet the criteria for inadequate response were randomized to double-blind treatment with adjunctive brexpiprazole or placebo (or quetiapine extended-release in Delphinus) for 6 weeks. Three studies used fixed doses of brexpiprazole and 3 used flexible doses; administered doses were in the range of 0.15--3 mg/d, depending on the study.

Assessments {#s9}
-----------

This publication focuses on the Sheehan Disability Scale (SDS) ([@CIT0021]; [@CIT0022]; [@CIT0023]), which was a key secondary efficacy outcome in each study. The SDS measures functional disability on 3 items: work/studies, social life, and family life. Patients use visual analogue scales to rate the extent to which each of these items has been disrupted by their symptoms, from 0 (not at all) to 10 (extremely). Patients can skip the work/studies item if they have not worked/studied in the last week for reasons unrelated to their disorder. The SDS mean score is calculated as the mean of the 3 individual item scores, or 2 items if work/studies is not reported (range 0 \[best functioning\] to 10 \[worst functioning\]). In all 6 studies, the SDS was completed at baseline (randomization) and week 6. In addition, Pyxis, Polaris, and Sirius collected SDS data at week 3 and Delphinus collected SDS data at weeks 2 and 4.

For details of the studies' primary efficacy outcomes (Montgomery--Åsberg Depression Rating Scale \[MADRS\] total score) and safety and tolerability outcomes, please refer to the primary publications and MDD clinical overviews ([@CIT0025], [@CIT0026], [@CIT0027], [@CIT0028]; [@CIT0017]; [@CIT0005], [@CIT0006]).

Data Analysis {#s10}
-------------

The brexpiprazole doses included in this post hoc analysis were 2 and 3 mg/d from the fixed-dose studies (the recommended dose range in MDD; [@CIT0018]) and 1--3 mg/d from the flexible-dose studies. Brexpiprazole doses of \<1 mg/d were investigated in some of the studies but were not included in this post hoc analysis because they are subtherapeutic doses. Four pooled groups were created to assess different aspects of brexpiprazole dosing: (1) fixed-dose studies (Pyxis, Polaris, Sirius), 2 and 3 mg/d; (2) flexible-dose studies (Delphinus, 211, 222), 1--3 mg/d; (3) phase 3 studies (Pyxis, Polaris, Sirius, Delphinus), 2--3 mg/d; and (4) all studies (Pyxis, Polaris, Sirius, Delphinus, 211, 222), 1--3 mg/d.

The analysis was performed in the target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase ([Table 1](#T1){ref-type="table"}). This definition was per final protocol for the phase 3 studies and was retrospectively applied to the phase 2 studies, for which the protocols had required that inadequate response criteria were met only at the end of prospective treatment. Within the target population, the randomized population comprised all patients who were randomized to double-blind medication, and the efficacy population was defined as all patients who took at least one dose of double-blind medication and who had a baseline and at least one post-baseline MADRS total evaluation in the randomized treatment phase.

Least squares (LS) mean changes from baseline (randomization) to week 6 of the randomized treatment phase, differences from placebo, and *P* values (2-sided tests at the 5% level) were calculated for the SDS mean and individual items. Cohen's *d* effect sizes were calculated for between-group differences. A mixed model for repeated measures (MMRM) was applied to the individual phase 3 studies, with model terms of treatment, site, visit, treatment-by-visit, and baseline-by-visit interaction as covariates. For the individual phase 2 studies, which had only one post-baseline SDS measurement, an ANCOVA model was used, with terms of treatment and site as main effects and baseline value as covariate. For the pooled analyses, MMRM was used but with the model term of site replaced by site nested within trial.

Finally, to investigate if the duration of MDD episode could influence the degree of functional change, Pearson correlation coefficients (*r*) were calculated between duration of current episode and change from baseline to week 6 in SDS mean/item scores.

Results {#s11}
=======

Patients {#s12}
--------

A total of 2066 patients were randomized to ADT + brexpiprazole at the doses of interest (n = 1034) or to ADT + placebo (n = 1032). Completion rates were high (≥90%) in both treatment groups ([Table 2](#T2){ref-type="table"}). The main reason for discontinuation in the ADT + brexpiprazole group was adverse events (2.8%) and in the ADT + placebo group was that the patient withdrew consent (2.8%).

###### 

Patient Disposition and Reasons for Discontinuation for All Studies Pooled (Randomized Population^*a*^)

  n (%)                        ADT + placebo (n = 1032)   ADT + brexpiprazole^*b*^ (n = 1034)
  ---------------------------- -------------------------- -------------------------------------
  Completed                    958 (92.8)                 931 (90.0)
  Discontinued                 74 (7.2)                   103 (10.0)
   Adverse event               8 (0.8)                    29 (2.8)
   Patient withdrew consent    29 (2.8)                   27 (2.6)
   Met withdrawal criteria     7 (0.7)                    19 (1.8)
   Protocol deviation          12 (1.2)                   11 (1.1)
   Lost to follow-up           5 (0.5)                    9 (0.9)
   Withdrawn by investigator   3 (0.3)                    5 (0.5)
   Lack of efficacy            10 (1.0)                   3 (0.3)
  Efficacy population^*a*^     1024 (99.2)                1018 (98.5)

Abbreviation: ADT, antidepressant treatment.

^a^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.

^*b*^The following brexpiprazole dose groups were included in the pooled analysis: Pyxis and Sirius, 2 mg/d; Polaris, 3 mg/d; Delphinus, 2--3 mg/d; study 211, 1.5 ± 0.5 mg/d; study 222, 1-- 3 mg/d.

Baseline demographic and clinical characteristics were similar between the treatment groups ([Table 3](#T3){ref-type="table"}). The mean age was 44 years, and two-thirds of patients were female. Mean (SD) SDS mean scores at baseline were 5.7 (2.1) in the ADT + brexpiprazole group and 5.8 (2.1) in the ADT + placebo group, indicating moderate impairment.

###### 

Baseline Demographic and Clinical Characteristics for All Studies Pooled (Efficacy Population^*a*^)

                                                                ADT + placebo (n = 1024)   ADT + brexpiprazole^*b*^ (n = 1018)
  ------------------------------------------------------------- -------------------------- -------------------------------------
  Demographic characteristics                                                              
   Age (y), mean (SD)                                           43.6 (11.8)                44.1 (11.7)
   Female, n (%)                                                707 (69.0)                 694 (68.2)
   White, n (%)^*c*^                                            855 (83.5)                 865 (85.0)
   BMI (kg/m^2^), mean (SD)                                     29.7 (7.3)                 29.6 (6.9)
  Clinical characteristics                                                                 
   Duration of current depressive episode (months), mean (SD)   18.8 (36.4)                18.0 (29.0)
   MADRS total score, mean (SD)                                 26.5 (5.8)                 26.5 (5.5)
   SDS mean score, mean (SD)                                    5.8 (2.1) (n = 993)        5.7 (2.1) (n = 981)
    SDS work/studies                                            5.4 (2.4) (n = 713)        5.3 (2.6) (n = 690)
    SDS social life                                             6.0 (2.3) (n = 993)        6.0 (2.3) (n = 982)
    SDS family life                                             5.7 (2.3) (n = 993)        5.7 (2.3) (n = 981)

Abbreviations: ADT, antidepressant treatment; BMI, body mass index; MADRS, Montgomery--Åsberg Depression Rating Scale; SD, standard deviation; SDS, Sheehan Disability Scale.

^*a*^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.

^*b*^The following brexpiprazole dose groups were included in the pooled analysis: Pyxis and Sirius, 2 mg/d; Polaris, 3 mg/d; Delphinus, 2--3 mg/d; study 211, 1.5 ± 0.5 mg/d; study 222, 1--3 mg/d.

^*c*^Race was not recorded for 1 patient in the ADT + brexpiprazole group and 1 patient in the ADT + placebo group.

Change in Functioning {#s13}
---------------------

In all 4 pooled analyses (fixed-dose studies, flexible-dose studies, phase 3 studies, and all studies), ADT + brexpiprazole showed a greater improvement in SDS mean score from baseline to week 6 than ADT + placebo (all *P* \< .01), with a treatment effect (between-group difference) of −0.4 points in each analysis ([Figure 1](#F1){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). The Cohen's *d* between-group effect size in the pooled analysis of all 6 studies was 0.22.

###### 

Mean Change in SDS Mean and Item Scores from Baseline to Week 6 (Efficacy Population^*a*^)

                                     SDS Mean                            SDS work/studies                  SDS social life                        SDS family life   
  ---------------------------------- -------------- -------------------- ------------------ -------------- ----------------- -------------------- ----------------- --------------------
  Fixed-dose studies, 2 and 3 mg/d   (n = 564)      (n = 555)            (n = 421)          (n = 400)      (n = 564)         (n = 555)            (n = 564)         (n = 555)
   Mean (SD) at baseline             5.83 (2.10)    5.81 (2.20)          5.35 (2.42)        5.42 (2.64)    6.07 (2.32)       6.07 (2.42)          5.80 (2.31)       5.77 (2.39)
   LS mean (SE) change to week 6     −1.03 (0.09)   −1.43 (0.09)\*\*\*   −1.04 (0.13)       −1.14 (0.13)   −1.10 (0.10)      −1.58 (0.11)\*\*\*   −0.97 (0.10)      −1.46 (0.10)\*\*\*
  Flexible-dose studies, 1--3 mg/d   (n = 429)      (n = 426)            (n = 292)          (n = 290)      (n = 429)         (n = 427)            (n = 429)         (n = 426)
   Mean (SD) at baseline             5.72 (2.05)    5.62 (2.01)          5.54 (2.34)        5.24 (2.47)    5.87 (2.22)       5.80 (2.16)          5.66 (2.23)       5.65 (2.22)
   LS mean (SE) change to week 6     −0.56 (0.11)   −0.97 (0.10)\*\*     −0.57 (0.13)       −0.82 (0.13)   −0.57 (0.12)      −0.99 (0.11)\*\*     −0.36 (0.12)      −0.88 (0.12)\*\*\*
  Phase 3 studies, 2--3 mg/d         (n = 769)      (n = 746)            (n = 557)          (n = 525)      (n = 769)         (n = 746)            (n = 769)         (n = 746)
   Mean (SD) at baseline             5.80 (2.06)    5.75 (2.09)          5.41 (2.34)        5.39 (2.47)    5.99 (2.25)       5.98 (2.28)          5.77 (2.24)       5.70 (2.29)
   LS mean (SE) change to week 6     −0.95 (0.08)   −1.31 (0.08)\*\*\*   −0.99 (0.10)       −1.04 (0.11)   −0.98 (0.08)      −1.42 (0.08)\*\*\*   −0.87 (0.08)      −1.34 (0.09)\*\*\*
  All studies, 1--3 mg/d             (n = 993)      (n = 981)            (n = 713)          (n = 690)      (n = 993)         (n = 982)            (n = 993)         (n = 981)
   Mean (SD) at baseline             5.78 (2.08)    5.73 (2.12)          5.43 (2.39)        5.34 (2.57)    5.98 (2.28)       5.95 (2.31)          5.74 (2.27)       5.72 (2.32)
   LS mean (SE) change to week 6     −0.80 (0.07)   −1.20 (0.07)\*\*\*   −0.81 (0.09)       −0.97 (0.09)   −0.84 (0.07)      −1.30 (0.07)\*\*\*   −0.67 (0.08)      −1.18 (0.08)\*\*\*

Abbreviations: ADT, antidepressant treatment; LS, least squares; MMRM, mixed model for repeated measures; SDS, Sheehan Disability Scale.

\*\**P* \< .01, \*\*\**P* \< .001 vs ADT + placebo; MMRM.

^*a*^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.

![Estimated treatment effect for antidepressant treatment (ADT) + brexpiprazole: mean change in Sheehan Disability Scale (SDS) mean score from baseline to week 6 (efficacy population^*^a^*^). Abbreviations: CI, confidence interval; LS, least squares; MMRM, mixed model for repeated measures. MMRM for Pyxis, Polaris, Sirius, and Delphinus; ANCOVA for Study 211 and Study 222; MMRM for pooled analyses. ^*^a^*^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.](pyy09501){#F1}

In each of the 6 individual studies, ADT + brexpiprazole showed a greater numerical improvement in SDS mean score from baseline to week 6 than ADT + placebo ([Figure 1](#F1){ref-type="fig"}). In 3 of the studies (Pyxis, Polaris, and Study 211), the benefit of ADT + brexpiprazole over ADT + placebo met the threshold of *P* \< .05.

Considering individual SDS items, in the pooled analysis of all 6 studies, ADT + brexpiprazole showed a greater benefit than ADT + placebo on the social life (LS mean difference: −0.45; 95% CI: −0.63, −0.27; *P* \< .001) and family life (−0.50; −0.70, −0.31; *P* \< .001) items, but not on the work/studies item (−0.16; −0.38, 0.06; *P* = .16) ([Figure 2](#F2){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). Cohen's *d* between-group effect sizes were 0.08 for work/studies, 0.23 for social life, and 0.23 for family life. The same pattern of benefits was observed in the other 3 pooled analyses (fixed-dose studies, flexible-dose studies, phase 3 studies), with benefits for ADT + brexpiprazole on the social life and family life items (all *P* \< .01) but not on the work/studies item ([Table 4](#T4){ref-type="table"}).

![Mean change in Sheehan Disability Scale (SDS) mean and item scores from baseline to week 6, for all studies pooled (efficacy population^a^). Abbreviations: ADT, antidepressant treatment; LS, least squares; MMRM, mixed model for repeated measures. \*\*\**P* \< .001 vs ADT + placebo; MMRM. ^*a*^Per target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222. ^*b*^The following brexpiprazole dose groups were included in the pooled analysis: Pyxis and Sirius, 2 mg/d; Polaris, 3 mg/d; Delphinus, 2--3 mg/d; study 211, 1.5 ± 0.5 mg/d; study 222, 1--3 mg/d.](pyy09502){#F2}

In the pooled analysis of all 6 studies, Pearson's *r* between duration of MDD episode and change in SDS mean score was 0.00 in the ADT + brexpiprazole group and 0.07 in the ADT + placebo group. Equivalent Pearson's *r* for the individual SDS items were: work/studies, 0.00 (ADT + brexpiprazole), 0.09 (ADT + placebo); social life, −0.02, 0.05; and family life, 0.00, 0.06.

Discussion {#s14}
==========

In these pooled analyses of over 2000 patients, adjunctive brexpiprazole improved functioning vs adjunctive placebo in patients with MDD, as measured by change in SDS mean score over 6 weeks of treatment. Each of the pooled analyses had a similar result, showing that the benefit of brexpiprazole over placebo was consistent between studies and not dependent on any one study. To the authors' knowledge, no minimal clinically important difference has been established for the SDS. In the pool of all 6 studies, SDS mean score decreased by 1.2 points with adjunctive brexpiprazole (from 5.7 at baseline), thereby approaching the threshold for functional response, suggested as ≤4 points by [@CIT0023]. The Cohen's *d* between-group effect size indicated a small but clinically meaningful benefit.

Other adjunctive treatments have also been assessed for their effect on functioning among patients with MDD and inadequate response to ADT. In a systematic review of 26 randomized, placebo-controlled studies of adjunctive agents, only aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning, as measured by the SDS total or mean score ([@CIT0030]). Of these agents, edivoxetine and risperidone are not indicated for the adjunctive treatment of MDD. In the adjunctive aripiprazole studies, SDS mean score decreased by 1.0--1.3 points over 6 weeks among patients taking aripiprazole ([@CIT0002], [@CIT0002]; [@CIT0014]; [@CIT0001]), similar to the score change with adjunctive brexpiprazole in the present analysis. However, use of aripiprazole in MDD is associated with a higher rate of akathisia than is seen with brexpiprazole ([@CIT0017]; [@CIT0003]).

In the present pooled analyses, adjunctive brexpiprazole showed a benefit over adjunctive placebo on the SDS items of social life and family life, but not on the work/studies item. Thus, the observed benefit on SDS mean was driven by the social life and family life items. This observation is in line with the systematic review of adjunctive agents in MDD (described above), which showed that the SDS work/studies item is generally unable to distinguish active treatment from placebo in short-term studies of patients with inadequate response to ADT ([@CIT0030]). In the systematic review, one posited explanation for this lack of sensitivity in MDD inadequate responders was that patients who were not working did not complete the work/studies item, meaning that the power to detect a treatment effect was reduced for this item. In the present study, only 71.1% of patients rated the work/studies item compared with other items at baseline, and thus we can assume that the other 28.9% of patients were not working, as might be expected in this population of persistent inadequate responders with a mean depressive episode duration of 1.5 years. However, due to the large population in this pooled analysis, loss of power is unlikely to explain the lack of effect on the work/studies item over 6 weeks. A more likely explanation is that the included studies were of insufficient duration to show a benefit. Patients with inadequate response to an initial ADT are prone to persistent impairment in occupational productivity, even after achieving remission of symptoms ([@CIT0029]). Thus, studies longer than 6 weeks may be needed for adjunctive brexpiprazole to show a benefit on the work/studies item. This hypothesis is supported by the results of a long-term, open-label study of adjunctive brexpiprazole in MDD, in which, over 6 to 12 months of treatment, patients improved by a similar amount on the work/studies item as on the social and family life items ([@CIT0007]).

There was negligible correlation (Pearson's *r* \< 0.1) between duration of current depressive episode and change from baseline to week 6 in SDS mean or item scores. Thus, episode duration did not affect the degree of functional improvement during this 6-week study. Furthermore, while they are clearly related, functional impairment cannot be fully explained by depressive symptom severity ([@CIT0031]). Studies examining the relationship between functioning and symptomatic rating scale outcomes have found moderate, but highly variable correlations ([@CIT0016]). Individual depressive symptoms also vary in their effect on functional impairment ([@CIT0004]; [@CIT0008]). Thus, the benefits of brexpiprazole augmentation on overall depression severity ([@CIT0025], [@CIT0026], [@CIT0027], [@CIT0028]; [@CIT0005], [@CIT0006]) are unlikely to fully account for the benefit in functioning observed in the present analysis.

Although the present analysis was limited by its post hoc nature, this allowed for a large sample size. In addition, as is the nature of randomized, controlled trials, the studied population may not be representative of patients in clinical practice due to the inclusion/exclusion criteria of the primary studies.

In conclusion, brexpiprazole, as adjunct to ADT, improves functioning in patients with MDD and inadequate response to ADTs. Specifically, benefits were observed for brexpiprazole over placebo in the domains of social and family life.

Funding {#s15}
=======

This work was supported by Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ) and H. Lundbeck A/S (Valby, Denmark).

Statement of Interest {#s16}
=====================

Mary Hobart, Peter Zhang, and Catherine Weiss are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. Stine Rasmussen Meehan and Hans Eriksson are full-time employees of H. Lundbeck A/S; Hans Eriksson also holds H. Lundbeck A/S stock.

Writing support was provided by Chris Watling, PhD, assisted by his colleagues at Cambridge Medical Communication Ltd (Cambridge, UK), and funded by Otsuka Pharmaceutical Development & Commercialization Inc. and H. Lundbeck A/S.
